Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Radiofrequency Ablation of Pulmonary Malignancy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00024076

Enrollment

Registered

2003-01-27

Start date

2000-05-31

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma

Keywords

recurrent non-small cell lung cancer, recurrent small cell lung cancer, recurrent malignant mesothelioma, recurrent thymoma and thymic carcinoma, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, pulmonary carcinoid tumor, lung metastases

Brief summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Detailed description

OBJECTIVES: * Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. * Determine the efficacy of this treatment, in terms of local control, in these patients. * Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Interventions

PROCEDUREradiofrequency ablation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diagnosis of a primary or secondary intrathoracic malignancy * Any cell type or origin * Involving the intrapulmonary, mediastinal, or pleural/chest wall * Inoperable primary or metastatic cancer to the lung * Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy) * Single or multiple lesions that are non-contiguous with vital structures or organs such as: * Trachea * Heart * Aorta * Great vessels * Esophagus * Less than 5 cm in largest dimension * Accessible via percutaneous transthoracic route * Hepatic: * Coagulation profile normal

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026